Government launches new program to make UK global partner of choice for R&D collaboration

26 October 2010

UK Science Minister David Willetts and Health Minister Lord Howe yesterday jointly launched a world-first initiative to boost partnership between academics, clinicians and the life sciences industry to deliver the medicines of the future faster to UK patients and to secure the UK’s position as the global partner of choice for R&D collaboration.

Coming hard on the heels of good news for life sciences from the UK Coalition government’s Comprehensive Spending Review (The Pharma Letter October 21) and £50 million ($78.4 million) from the Technology Strategy Board (TSB) for stratified medicine, the new initiatives were launched at a joint Association of the British Pharmaceutical Industry (ABPI)/BioIndustry Association (BIA) conference in London.

These initiatives are the Therapeutic Capability Clusters led by the Office for Strategic Coordination of Health and Research (OSCHR) and the Medical Research Council (MRC)/ABPI Inflammation and Immunology Initiative.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >